Small cell lung cancer (SCLC) is an aggressive type of lung cancer characterized by rapid growth and a tendency to spread to other parts of the body at an early stage. It accounts for approximately 10–15% of lung cancers and is strongly associated with cigarette smoking. Although SCLC can progress quickly, it is often sensitive to chemotherapy and radiation therapy, and advances in immunotherapy have added important treatment options.

Because SCLC can spread rapidly, small cell lung cancer early diagnosis, accurate staging and prompt treatment are important. Treatment is usually planned by a multidisciplinary team that may include pulmonologists, medical oncologists, radiation oncologists, radiologists, pathologists and other specialists.

What Is Small Cell Lung Cancer?

Small cell lung cancer gets its name from the appearance of the cancer cells under a microscope. The cells are typically smaller than those seen in non-small cell lung cancer and have distinctive microscopic characteristics.

SCLC is generally divided into two broad clinical categories:

• Limited-stage SCLC: Cancer is confined to one side of the chest and can generally be encompassed within a tolerable radiation field.

• Extensive-stage SCLC: Cancer has spread beyond the area that can be treated as limited-stage disease, including distant organs or the opposite side of the chest.

Unlike many early-stage non-small cell lung cancers, surgery plays a relatively limited role in SCLC because the disease frequently spreads before it is detected.

Symptoms of Small Cell Lung Cancer

Early SCLC may not cause obvious symptoms. As the tumor grows or spreads, patients may develop respiratory and systemic symptoms.

Common symptoms include:

• Persistent or worsening cough

• Shortness of breath

• Chest pain or discomfort

• Wheezing

• Coughing up blood

• Recurrent chest infections

• Unexplained weight loss

• Loss of appetite

• Persistent tiredness or weakness

• Hoarseness

Because SCLC can spread to the brain, bones, liver and other organs, symptoms may also depend on where the cancer has spread. Headaches, confusion, weakness, seizures or neurological changes require prompt medical assessment.

Risk Factors

Cigarette smoking is the strongest known risk factor for small cell lung cancer. The risk generally increases with the duration and amount of tobacco exposure. Exposure to second-hand smoke can also contribute to lung cancer risk.

Other environmental and occupational exposures may contribute to lung cancer risk. A person's overall risk can also be influenced by age, previous lung disease and other individual factors.

Stopping smoking is important at every stage. Patients who stop smoking after diagnosis may improve their overall health and ability to tolerate cancer treatment.

How Is Small Cell Lung Cancer Diagnosed?

Diagnosis usually begins with a medical history, physical examination and imaging. A chest CT scan can identify a suspicious lung mass and assess nearby lymph nodes. PET-CT may be used to evaluate the extent of disease.

A tissue diagnosis is generally required. Depending on the location of the tumor, tissue may be obtained through bronchoscopy, endobronchial ultrasound (EBUS), CT-guided biopsy or another appropriate biopsy technique.

A pathologist examines the tissue to determine whether the tumor is consistent with SCLC. Additional testing may be performed when clinically appropriate.

Because SCLC has a high tendency to spread to the brain, doctors may recommend MRI of the brain as part of staging. Other investigations may be used to evaluate the liver, bones, adrenal glands and other potential sites of spread.

Staging of Small Cell Lung Cancer

SCLC is commonly described using the limited-stage and extensive-stage system.

Limited-Stage SCLC

In limited-stage disease, the cancer is generally restricted to one side of the chest and nearby lymph nodes and can potentially be treated within a single radiation field.

The usual treatment approach involves a combination of chemotherapy and thoracic radiation therapy in appropriate patients.small cell lung cancer

Extensive-Stage SCLC

Extensive-stage SCLC has spread more widely, such as to the opposite lung, distant lymph nodes or other organs.

Treatment is generally systemic because cancer cells may be present throughout the body.

Treatment Options for SCLC

Treatment depends on the stage of disease, overall health, symptoms, organ function and response to treatment.

Chemotherapy

Chemotherapy remains a major component of SCLC treatment. Commonly used regimens include a platinum-based drug combined with etoposide.

Chemotherapy can be used for both limited-stage and extensive-stage disease, although the overall treatment strategy differs according to stage.

Radiation Therapy

Radiation therapy can be used to treat the primary tumor and affected lymph nodes in limited-stage disease. It may also be used to relieve symptoms caused by tumors that have spread to areas such as the brain or bones.

In selected patients who respond well to initial treatment, doctors may discuss radiation to the brain, although the approach is individualized and brain MRI surveillance is increasingly important in treatment planning.

Immunotherapy

Immunotherapy has become an important part of treatment for many patients with extensive-stage SCLC. Immune checkpoint inhibitors may be combined with platinum-based chemotherapy as initial treatment for eligible patients.

The specific treatment depends on the patient's medical condition, treatment eligibility and current clinical guidelines.

Clinical Trials

Clinical trials continue to investigate new treatments for SCLC, including novel immunotherapies, targeted approaches, antibody-drug conjugates and other therapies. Patients may benefit from discussing clinical-trial opportunities with their oncology team.

Role of Bronchoscopy and EBUS

Bronchoscopy can be useful when a suspected lung cancer is located within or close to the airways. During bronchoscopy, a specialist can examine the breathing passages and obtain tissue samples.

EBUS-TBNA (endobronchial ultrasound-guided transbronchial needle aspiration) can help sample lymph nodes in the chest. This can provide important information for diagnosis and staging while avoiding more invasive procedures in selected patients